• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

子宫浆液性癌中体细胞单核苷酸和拷贝数突变的全景

Landscape of somatic single-nucleotide and copy-number mutations in uterine serous carcinoma.

机构信息

Department of Genetics, Howard Hughes Medical Institute, Yale University School of Medicine, New Haven, CT 06510, USA.

出版信息

Proc Natl Acad Sci U S A. 2013 Feb 19;110(8):2916-21. doi: 10.1073/pnas.1222577110. Epub 2013 Jan 28.

DOI:10.1073/pnas.1222577110
PMID:23359684
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC3581983/
Abstract

Uterine serous carcinoma (USC) is a biologically aggressive subtype of endometrial cancer. We analyzed the mutational landscape of USC by whole-exome sequencing of 57 cancers, most of which were matched to normal DNA from the same patients. The distribution of the number of protein-altering somatic mutations revealed that 52 USC tumors had fewer than 100 (median 36), whereas 5 had more than 3,000 somatic mutations. The mutations in these latter tumors showed hallmarks of defects in DNA mismatch repair. Among the remainder, we found a significantly increased burden of mutation in 14 genes. In addition to well-known cancer genes (i.e., TP53, PIK3CA, PPP2R1A, KRAS, FBXW7), there were frequent mutations in CHD4/Mi2b, a member of the NuRD-chromatin-remodeling complex, and TAF1, an element of the core TFIID transcriptional machinery. Additionally, somatic copy-number variation was found to play an important role in USC, with 13 copy-number gains and 12 copy-number losses that occurred more often than expected by chance. In addition to loss of TP53, we found frequent deletion of a small segment of chromosome 19 containing MBD3, also a member of the NuRD-chromatin-modification complex, and frequent amplification of chromosome segments containing PIK3CA, ERBB2 (an upstream activator of PIK3CA), and CCNE1 (a target of FBXW7-mediated ubiquitination). These findings identify frequent mutation of DNA damage, chromatin remodeling, cell cycle, and cell proliferation pathways in USC and suggest potential targets for treatment of this lethal variant of endometrial cancer.

摘要

子宫浆液性癌(USC)是一种生物学侵袭性的子宫内膜癌亚型。我们通过对 57 例癌症进行全外显子组测序,分析了 USC 的突变图谱,其中大多数与同一患者的正常 DNA 相匹配。蛋白改变的体细胞突变数量分布表明,52 例 USC 肿瘤的突变数少于 100(中位数 36),而 5 例肿瘤的突变数超过 3000。这些后者肿瘤的突变显示出 DNA 错配修复缺陷的特征。在其余肿瘤中,我们发现 14 个基因的突变负担显著增加。除了众所周知的癌症基因(即 TP53、PIK3CA、PPP2R1A、KRAS、FBXW7)外,NuRD-染色质重塑复合物的成员 CHD4/Mi2b 和核心 TFIID 转录机器的元件 TAF1 也经常发生突变。此外,体细胞拷贝数变异在 USC 中也起着重要作用,13 个拷贝数增益和 12 个拷贝数缺失比预期的随机事件更频繁发生。除了 TP53 的缺失,我们还发现了含有 MBD3 的小染色体 19 片段的频繁缺失,MBD3 也是 NuRD-染色质修饰复合物的成员,以及包含 PIK3CA、ERBB2(PIK3CA 的上游激活物)和 CCNE1(FBXW7 介导的泛素化的靶标)的染色体片段的频繁扩增。这些发现确定了 USC 中 DNA 损伤、染色质重塑、细胞周期和细胞增殖途径的频繁突变,并为治疗这种致命的子宫内膜癌变体提供了潜在的治疗靶点。

相似文献

1
Landscape of somatic single-nucleotide and copy-number mutations in uterine serous carcinoma.子宫浆液性癌中体细胞单核苷酸和拷贝数突变的全景
Proc Natl Acad Sci U S A. 2013 Feb 19;110(8):2916-21. doi: 10.1073/pnas.1222577110. Epub 2013 Jan 28.
2
Identification of molecular pathway aberrations in uterine serous carcinoma by genome-wide analyses.通过全基因组分析鉴定子宫浆液性癌中的分子通路异常。
J Natl Cancer Inst. 2012 Oct 3;104(19):1503-13. doi: 10.1093/jnci/djs345. Epub 2012 Aug 23.
3
Mutational landscape of uterine and ovarian carcinosarcomas implicates histone genes in epithelial-mesenchymal transition.子宫和卵巢癌肉瘤的突变图谱表明组蛋白基因与上皮-间质转化有关。
Proc Natl Acad Sci U S A. 2016 Oct 25;113(43):12238-12243. doi: 10.1073/pnas.1614120113. Epub 2016 Oct 10.
4
Dual CCNE1/PIK3CA targeting is synergistic in CCNE1-amplified/PIK3CA-mutated uterine serous carcinomas in vitro and in vivo.在体外和体内,双重靶向CCNE1/PIK3CA对CCNE1扩增/PIK3CA突变的子宫浆液性癌具有协同作用。
Br J Cancer. 2016 Jul 26;115(3):303-11. doi: 10.1038/bjc.2016.198. Epub 2016 Jun 28.
5
Identification of potential therapeutic targets by molecular profiling of 628 cases of uterine serous carcinoma.通过对628例子宫浆液性癌进行分子谱分析来鉴定潜在治疗靶点
Gynecol Oncol. 2015 Sep;138(3):620-6. doi: 10.1016/j.ygyno.2015.06.034. Epub 2015 Jun 26.
6
The genetic landscape of metaplastic breast cancers and uterine carcinosarcomas.多形性乳腺癌和子宫癌肉瘤的遗传景观。
Mol Oncol. 2021 Apr;15(4):1024-1039. doi: 10.1002/1878-0261.12813. Epub 2021 Feb 19.
7
Whole-exome sequencing of cervical carcinomas identifies activating ERBB2 and PIK3CA mutations as targets for combination therapy.宫颈癌全外显子组测序鉴定出 ERBB2 和 PIK3CA 突变作为联合治疗的靶点。
Proc Natl Acad Sci U S A. 2019 Nov 5;116(45):22730-22736. doi: 10.1073/pnas.1911385116. Epub 2019 Oct 17.
8
Integrated Molecular Characterization of Uterine Carcinosarcoma.子宫癌肉瘤的综合分子特征分析
Cancer Cell. 2017 Mar 13;31(3):411-423. doi: 10.1016/j.ccell.2017.02.010.
9
The FOXA2 transcription factor is frequently somatically mutated in uterine carcinosarcomas and carcinomas.FOXA2转录因子在子宫癌肉瘤和癌中经常发生体细胞突变。
Cancer. 2018 Jan 1;124(1):65-73. doi: 10.1002/cncr.30971. Epub 2017 Sep 21.
10
Molecular alterations of EGFR and PIK3CA in uterine serous carcinoma.子宫浆液性癌中EGFR和PIK3CA的分子改变
Gynecol Oncol. 2009 Jun;113(3):370-3. doi: 10.1016/j.ygyno.2008.12.021. Epub 2009 Mar 9.

引用本文的文献

1
HER2/neu as a Signaling and Therapeutic Marker in Uterine Serous Carcinoma.HER2/neu作为子宫浆液性癌中的信号传导及治疗标志物
Cells. 2025 Aug 19;14(16):1282. doi: 10.3390/cells14161282.
2
Preclinical Activity of Datopotamab Deruxtecan (Dato-DXd), an Antibody-Drug Conjugate Targeting TROP2, in Poorly Differentiated Endometrial Carcinomas.靶向TROP2的抗体药物偶联物达泊托单抗德卢替康(Dato-DXd)在低分化子宫内膜癌中的临床前活性
Cancer Res Commun. 2025 Sep 1;5(9):1611-1620. doi: 10.1158/2767-9764.CRC-25-0251.
3
Carcinosarcoma of the Endometrium-Pathology, Molecular Landscape and Novel Therapeutic Approaches.子宫内膜癌肉瘤——病理学、分子格局与新型治疗方法
Medicina (Kaunas). 2025 Jun 26;61(7):1156. doi: 10.3390/medicina61071156.
4
Functional impact of the hyperduplication genomophenotype in high copy number endometrial cancer.高拷贝数子宫内膜癌中基因表型超复制的功能影响
iScience. 2025 Jun 7;28(7):112850. doi: 10.1016/j.isci.2025.112850. eCollection 2025 Jul 18.
5
Generation and characterization of a mouse model of conditional knockout in the endometrial epithelium.子宫内膜上皮条件性敲除小鼠模型的构建与鉴定
bioRxiv. 2025 Jun 8:2025.06.05.658183. doi: 10.1101/2025.06.05.658183.
6
Preclinical Activity of Datopotamab Deruxtecan, an Antibody-Drug Conjugate Targeting Trophoblast Cell-Surface Antigen 2, in Uterine Serous Carcinoma.靶向滋养层细胞表面抗原2的抗体药物偶联物达波妥单抗德鲁替康在子宫浆液性癌中的临床前活性
Cancer Res Commun. 2025 May 1;5(5):774-782. doi: 10.1158/2767-9764.CRC-25-0057.
7
Updates and controversies in the management of uterine serous carcinoma and uterine carcinosarcoma.子宫浆液性癌和子宫癌肉瘤治疗的进展与争议
Int J Gynecol Cancer. 2025 Mar;35(3):101672. doi: 10.1016/j.ijgc.2025.101672. Epub 2025 Jan 30.
8
Functional Profiling of p53 and RB Cell Cycle Regulatory Proficiency Suggests Mechanism-Driven Molecular Stratification in Endometrial Carcinoma.p53和RB细胞周期调控能力的功能分析提示子宫内膜癌中存在机制驱动的分子分层。
Cancer Res Commun. 2025 Apr 1;5(4):719-742. doi: 10.1158/2767-9764.CRC-24-0028.
9
Cyclin E1/CDK2 activation defines a key vulnerability to WEE1 kinase inhibition in gynecological cancers.细胞周期蛋白E1/细胞周期蛋白依赖性激酶2的激活确定了妇科癌症中对WEE1激酶抑制的关键易感性。
NPJ Precis Oncol. 2025 Jan 4;9(1):3. doi: 10.1038/s41698-024-00787-4.
10
The Diverse Aspects of Uterine Serous Cancer: an NCI workshop on the status of and opportunities for advancement of research.子宫浆液性癌的多方面研究:美国国立癌症研究所关于研究现状与进展机遇的研讨会
J Natl Cancer Inst. 2025 May 1;117(5):833-839. doi: 10.1093/jnci/djae277.

本文引用的文献

1
Exome sequencing of serous endometrial tumors identifies recurrent somatic mutations in chromatin-remodeling and ubiquitin ligase complex genes.对浆液性子宫内膜肿瘤的外显子组测序鉴定出染色质重塑和泛素连接酶复合物基因中的反复发生的体细胞突变。
Nat Genet. 2012 Dec;44(12):1310-5. doi: 10.1038/ng.2455. Epub 2012 Oct 28.
2
Identification of molecular pathway aberrations in uterine serous carcinoma by genome-wide analyses.通过全基因组分析鉴定子宫浆液性癌中的分子通路异常。
J Natl Cancer Inst. 2012 Oct 3;104(19):1503-13. doi: 10.1093/jnci/djs345. Epub 2012 Aug 23.
3
Comprehensive molecular characterization of human colon and rectal cancer.全面的人类结肠和直肠癌分子特征分析。
Nature. 2012 Jul 18;487(7407):330-7. doi: 10.1038/nature11252.
4
Phosphorylation-dependent regulation of cyclin D1 and cyclin A gene transcription by TFIID subunits TAF1 and TAF7.TFIID 亚基 TAF1 和 TAF7 通过磷酸化依赖性调节细胞周期蛋白 D1 和细胞周期蛋白 A 基因转录。
Mol Cell Biol. 2012 Aug;32(16):3358-69. doi: 10.1128/MCB.00416-12. Epub 2012 Jun 18.
5
Exome sequencing identifies recurrent SPOP, FOXA1 and MED12 mutations in prostate cancer.外显子组测序鉴定前列腺癌中 SPOP、FOXA1 和 MED12 的高频突变。
Nat Genet. 2012 May 20;44(6):685-9. doi: 10.1038/ng.2279.
6
IDH1 mutation is sufficient to establish the glioma hypermethylator phenotype.IDH1 突变足以建立起胶质瘤高甲基化表型。
Nature. 2012 Feb 15;483(7390):479-83. doi: 10.1038/nature10866.
7
Cancer statistics, 2012.癌症统计数据,2012 年。
CA Cancer J Clin. 2012 Jan-Feb;62(1):10-29. doi: 10.3322/caac.20138. Epub 2012 Jan 4.
8
Development of targeted therapy in uterine serous carcinoma, a biologically aggressive variant of endometrial cancer.子宫浆液性癌是子宫内膜癌的一种生物学侵袭性变体,针对其的靶向治疗的发展。
Expert Rev Anticancer Ther. 2012 Jan;12(1):41-9. doi: 10.1586/era.11.192.
9
Exome sequencing identifies frequent mutation of ARID1A in molecular subtypes of gastric cancer.外显子组测序鉴定出胃癌分子亚型中 ARID1A 的高频突变。
Nat Genet. 2011 Oct 30;43(12):1219-23. doi: 10.1038/ng.982.
10
Cyclin D as a therapeutic target in cancer.细胞周期蛋白 D 作为癌症治疗靶点。
Nat Rev Cancer. 2011 Jul 7;11(8):558-72. doi: 10.1038/nrc3090.